GSK vs. CCH.L
GSK (GlaxoSmithKline plc) and CCH.L (Coca Cola HBC AG) are both stocks. GSK operates in Drug Manufacturers - General (Healthcare), while CCH.L operates in Beverages - Non-Alcoholic (Consumer Defensive). Over the past 10 years, GSK returned 5.35%/yr vs 15.75%/yr for CCH.L. At a 0.30 correlation, their price movements are largely independent.
Performance
GSK vs. CCH.L - Performance Comparison
Loading charts...
Different Trading Currencies
GSK is traded in USD, while CCH.L is traded in GBp. To make them comparable, the CCH.L values have been converted to USD using the latest available exchange rates.
Returns By Period
In the year-to-date period, GSK achieves a 9.89% return, which is significantly lower than CCH.L's 21.78% return. Over the past 10 years, GSK has underperformed CCH.L with an annualized return of 5.35%, while CCH.L has yielded a comparatively higher 15.75% annualized return.
GSK
- 1D
- 0.34%
- 1M
- 4.84%
- YTD
- 9.89%
- 6M
- 10.40%
- 1Y
- 29.34%
- 3Y*
- 19.84%
- 5Y*
- 5.34%
- 10Y*
- 5.35%
CCH.L
- 1D
- 1.12%
- 1M
- 9.18%
- YTD
- 21.78%
- 6M
- 27.45%
- 1Y
- 16.85%
- 3Y*
- 30.92%
- 5Y*
- 14.37%
- 10Y*
- 15.75%
GSK vs. CCH.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 9.89% | 51.23% | -5.14% | 9.71% | -33.41% | 26.74% | -17.72% | 29.24% | 13.79% | -2.97% |
CCH.L Coca Cola HBC AG | 21.78% | 54.77% | 20.11% | 26.42% | -28.26% | 9.16% | -1.77% | 15.54% | -2.58% | 52.26% |
Correlation
The correlation between GSK and CCH.L is 0.33, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.33 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.29 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.29 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.29 |
Correlation (All Time) Calculated using the full available price history since Apr 29, 2013 | 0.30 |
Fundamentals
GSK:
$108.04B
CCH.L:
£16.70B
GSK:
£2.85
CCH.L:
€4.84
GSK:
13.90
CCH.L:
10.98
GSK:
0.93
CCH.L:
0.61
GSK:
2.47
CCH.L:
0.86
GSK:
3.42
CCH.L:
5.03
GSK:
£32.78B
CCH.L:
€22.35B
GSK:
£23.87B
CCH.L:
€8.14B
GSK:
£11.30B
CCH.L:
€3.00B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GSK vs. CCH.L — Risk / Return Rank
GSK
CCH.L
GSK vs. CCH.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and Coca Cola HBC AG (CCH.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GSK | CCH.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.38 | ||
| Sortino ratioReturn per unit of downside risk | +0.50 | ||
| Omega ratioGain probability vs. loss probability | 1.20 | 1.15 | +0.06 |
| Calmar ratioReturn relative to maximum drawdown | 1.58 | 0.88 | +0.70 |
| Martin ratioReturn relative to average drawdown | 3.92 | 1.72 | +2.20 |
Loading charts...
Drawdowns
GSK vs. CCH.L - Drawdown Comparison
The maximum GSK drawdown since its inception was -55.70%, which is greater than CCH.L's maximum drawdown of -52.49%. Use the drawdown chart below to compare losses from any high point for GSK and CCH.L.
Loading charts...
Drawdown Indicators
| GSK | CCH.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -55.70% | -52.49% | -3.21% |
Max Drawdown (1Y)Largest decline over 1 year | -18.63% | -19.11% | +0.48% |
Max Drawdown (3Y)Largest decline over 3 years | -28.46% | -20.00% | -8.46% |
Max Drawdown (5Y)Largest decline over 5 years | -50.10% | -50.65% | +0.55% |
Max Drawdown (10Y)Largest decline over 10 years | -50.10% | -52.49% | +2.39% |
Current DrawdownCurrent decline from peak | -11.92% | -3.79% | -8.13% |
Average DrawdownAverage peak-to-trough decline | -18.87% | -17.86% | -1.01% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.28% | 9.75% | -1.47% |
Volatility
GSK vs. CCH.L - Volatility Comparison
GlaxoSmithKline plc (GSK) has a higher volatility of 6.81% compared to Coca Cola HBC AG (CCH.L) at 5.60%. This indicates that GSK's price experiences larger fluctuations and is considered to be riskier than CCH.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GSK | CCH.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.81% | 5.60% | +1.21% |
Volatility (6M)Calculated over the trailing 6-month period | 18.49% | 17.28% | +1.21% |
Volatility (1Y)Calculated over the trailing 1-year period | 27.06% | 23.56% | +3.50% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 25.08% | 26.29% | -1.21% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.89% | 28.19% | -5.30% |
Dividends
GSK vs. CCH.L - Dividend Comparison
GSK's dividend yield for the trailing twelve months is around 3.26%, more than CCH.L's 2.26% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CCH.L Coca Cola HBC AG | 2.26% | 2.33% | 2.96% | 2.94% | 3.60% | 2.50% | 2.35% | 6.99% | 1.95% | 1.60% | 1.88% | 1.76% |
GSK GlaxoSmithKline plc | 3.26% | 3.42% | 4.60% | 3.75% | 5.47% | 4.99% | 5.59% | 4.35% | 5.65% | 5.83% | 6.86% | 5.93% |
Financials
GSK vs. CCH.L - Financials Comparison
This section allows you to compare key financial metrics between GlaxoSmithKline plc and Coca Cola HBC AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GSK vs. CCH.L - Profitability Comparison
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.
CCH.L - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Coca Cola HBC AG reported a gross profit of 2.20B and revenue of 5.98B. Therefore, the gross margin over that period was 36.8%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.
CCH.L - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Coca Cola HBC AG reported an operating income of 654.01M and revenue of 5.98B, resulting in an operating margin of 10.9%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.
CCH.L - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Coca Cola HBC AG reported a net income of 469.16M and revenue of 5.98B, resulting in a net margin of 7.9%.
Frequently Asked Questions
GSK and CCH.L have a correlation of 0.33, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for GSK and CCH.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer